Recombinant bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy: current strategies

被引：8

作者：

Wang, Yonghua ^{[1
]}

Yang, Meng ^{[1
]}

Yu, Qinchao ^{[1
]}

Yu, Lun ^{[1
]}

Shao, Shixiu ^{[1
]}

Wang, Xinsheng ^{[1
]}

机构：

[1] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266071, Peoples R China

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 01期

基金：

中国国家自然科学基金;

关键词：

bacillus Calmette-Guerin; BCG; immunotherapy; intravesical therapy; recombinant BCG; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; EXPRESSING PERTUSSIS TOXIN; GAMMA-INDUCING FACTOR; MYCOBACTERIUM-BOVIS; IFN-GAMMA; INTRAVESICAL THERAPY; DNA VACCINES; MITOMYCIN-C; TH1-STIMULATING CYTOKINES; PLUS INTERFERON-ALPHA-2B;

D O I：

10.1586/14737140.2015.961430

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bacillus Calmette-Guerin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have focused on recombinant BCG (rBCG) which provides a novel tactic for modification of BCG. To date, a number of rBCG strains have been developed and demonstrated to encourage efficacy and safety in preclinical and clinical studies. This review summarizes current rBCG strategies, concerns and future directions in UBC immunotherapy with an intention to encourage further research and eventually to inform clinical decisions.

引用

页码：85 / 93

页数：9

共 50 条

[41] Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guerin unresponsive bladder cancer
Shariat, Shahrokh F.
Enikeev, Dmitry V.
Mostafaei, Hadi
IMMUNOTHERAPY, 2019, 11 (13) : 1083 - 1086
[42] The immunotherapeutic effects of recombinant Bacillus Calmette-Guerin resistant to antimicrobial peptides on bladder cancer cells
Cho, Min-Ji
Kim, Myeong Joo
Kim, Kijeong
Choi, Young Wook
Lee, Sang-Jin
Whang, Young Mi
Chang, In Ho
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 509 (01) : 167 - 174
[43] Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer
Sylvester, Richard J.
INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (02) : 113 - 120
[44] Bacillus Calmette-Guerin for Upper Tract Urothelial Cancer: Is There a Role?
Rastinehad, Ardeshir R.
Smith, Arthur D.
JOURNAL OF ENDOUROLOGY, 2009, 23 (04) : 563 - 568
[45] The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette-Guerin in Superficial Bladder Cancer: a Preliminary Study
Cho, D. Y.
Bae, J. H.
Moon, D. G.
Cheon, J.
Lee, J. G.
Kim, J. J.
Yoon, D. K.
Park, H. S.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (06) : 1823 - 1830
[46] Maintenance Bacillus Calmette-Guerin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer
Lamm, Donald
Persad, Raj
Colombel, Marc
Brausi, Maurizio
EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (09) : 715 - 734
[47] Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review
Saluja, Manmeet
Gilling, Peter
INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (01) : 18 - 24
[48] MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy
Yuan, Shifang
Shi, Changhong
Liu, Li
Han, Wei
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (07) : 1037 - 1048
[49] Strategies for Optimizing Bacillus Calmette-Guerin
Shah, Jay B.
Kamat, Ashish M.
UROLOGIC CLINICS OF NORTH AMERICA, 2013, 40 (02) : 211 - +
[50] FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
Zhang, Yang
Huo, Fan
Cao, Qiang
Jia, Ru
Huang, Qiju
Wang, Zhu A.
Theodorescu, Dan
Lv, Qiang
Li, Pengchao
Yan, Chao
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)

← 1 2 3 4 5 →